标题
Design and in vivo activity of A3 adenosine receptor agonist prodrugs
作者
关键词
-
出版物
Purinergic Signalling
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-28
DOI
10.1007/s11302-020-09715-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
- (2020) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- 280-LB: Role of A1 and A3 Adenosine Receptors in Whole Body Glucose Metabolism
- (2019) SHANU JAIN et al. DIABETES
- TGF-β induces liver fibrosis via miRNA-181a-mediated down regulation of augmenter of liver regeneration in hepatic stellate cells
- (2019) Parul Gupta et al. PLoS One
- Smooth Muscle α-Actin Deficiency Leads to Decreased Liver Fibrosis via Impaired Cytoskeletal Signaling in Hepatic Stellate Cells
- (2019) Don C. Rockey et al. AMERICAN JOURNAL OF PATHOLOGY
- The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice
- (2019) Pnina Fishman et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- The expanding role of prodrugs in contemporary drug design and development
- (2018) Jarkko Rautio et al. NATURE REVIEWS DRUG DISCOVERY
- Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms
- (2018) Carrie Wahlman et al. PAIN
- Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH
- (2018) Daniela Carmen Oniciu et al. PLoS One
- Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma
- (2018) Kazuki Takakura et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson
- (2018) Shira Cohen et al. Journal of Immunology Research
- Pathology of non-alcoholic fatty liver disease
- (2017) Pierre Bedossa LIVER INTERNATIONAL
- A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy
- (2017) Kenneth A. Jacobson et al. MEDICINAL RESEARCH REVIEWS
- Identification of A3adenosine receptor agonists as novel non-narcotic analgesics
- (2016) K Janes et al. BRITISH JOURNAL OF PHARMACOLOGY
- The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis
- (2016) Pnina Fishman et al. CLINICAL RHEUMATOLOGY
- Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice
- (2016) Keisuke Yokohama et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy
- (2016) Gil Ohana et al. Molecular Medicine Reports
- History and Perspectives of A2AAdenosine Receptor Antagonists as Potential Therapeutic Agents
- (2015) Delia Preti et al. MEDICINAL RESEARCH REVIEWS
- Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain
- (2015) Dilip K. Tosh et al. Purinergic Signalling
- Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly
- (2015) Q. Fu et al. Scientific Reports
- Probing biased/partial agonism at the G protein-coupled A2B adenosine receptor
- (2014) Zhan-Guo Gao et al. BIOCHEMICAL PHARMACOLOGY
- In Vivo Phenotypic Screening for Treating Chronic Neuropathic Pain: Modification of C2-Arylethynyl Group of Conformationally Constrained A3 Adenosine Receptor Agonists
- (2014) Dilip K. Tosh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Wnt signaling in liver fibrosis: Progress, challenges and potential directions
- (2013) Cheng-gui Miao et al. BIOCHIMIE
- CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
- (2013) S. M. Stemmer et al. ONCOLOGIST
- Structure-Guided Design of A3 Adenosine Receptor-Selective Nucleosides: Combination of 2-Arylethynyl and Bicyclo[3.1.0]hexane Substitutions
- (2012) Dilip K. Tosh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Automated design of ligands to polypharmacological profiles
- (2012) Jérémy Besnard et al. NATURE
- Absorption and Metabolism of Chlorogenic Acids in Cultured Gastric Epithelial Monolayers
- (2011) T. L. Farrell et al. DRUG METABOLISM AND DISPOSITION
- Endpoints and clinical trial design for nonalcoholic steatohepatitis
- (2011) Arun J. Sanyal et al. HEPATOLOGY
- Synthesis, Characterization and Biological Evaluation of Succinate Prodrugs of Curcuminoids for Colon Cancer Treatment
- (2011) Wisut Wichitnithad et al. MOLECULES
- A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release
- (2011) Katia Varani et al. ARTHRITIS RESEARCH & THERAPY
- Soluble polyphenols: Synthesis and bioavailability of 3,4′,5-tri(α-d-glucose-3-O-succinyl) resveratrol
- (2009) Lucia Biasutto et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease
- (2009) A. Ochaion et al. CELLULAR IMMUNOLOGY
- Design of (N)-methanocarba adenosine 5′-uronamides as species-independent A3 receptor-selective agonists
- (2008) Artem Melman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Synthesis and Properties of a New Water-Soluble Prodrug of the Adenosine A2A Receptor Antagonist MSX-2
- (2008) Karl Vollmann et al. MOLECULES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now